

B¹ cont 60. (new) The method of claim 59, further comprising recovering the polypeptide from the culture medium.--

REMARKS

In response to the restriction requirement imposed in the Office Action issued March 1, 2002 in the above-captioned application, Applicant hereby elects Group I drawn to an isolated nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO:1, encoding the polypeptide comprising SEQ ID NO:2, an expression vector, a recombinant host cell and a method of producing the encoded protein. This election is made without traverse, though the Applicant reserves the right to pursue the non-elected claims at a later time.

Applicant has canceled claims 1-33 and added new claims 34-60, which relate to the subject matter of the canceled claims. New claims 34-60 are derived from the elected claims 1-9 and 23-31 as follows:

<u>New Claim</u>	<u>Canceled Claim</u>
39	1
40	2, 5
34, 37, 38	3
35, 36	-
41-47	7-8
48-54	23
55-58	31
59	24
60	30

This amendment is fully supported by the specification. For example, support for claims 34-36 can be found on page 16, lines 6-23, support for claim 37-40 can be found on page 12, lines 18-23 to page 13, lines 1-5, support for claims 41-47 can be found on page 30, lines 10-26, support for claims 48-54, claims 55-58 and claim 59 can be found on pages 25-31, and support for claim 60 can be found on page 31, of the specification as originally filed.

Applicant has provided a new title to more accurately reflect the subject matter of the elected invention.

No new matter has been introduced by these amendments.

CONCLUSION


Applicant respectfully submits that each of the pending claims of the subject application is in condition for allowance. If any issues remain after consideration of this

Immunex Corporation
USSN 09/598,443

Attorney Docket No. 2007-US

Response, the Examiner is invited to telephone the below-indicated representative of the Applicant to discuss resolution thereof.

Respectfully submitted,




Randolph N. Mohr, Ph.D.
Patent Agent
Registration No. 45,590
DIRECT DIAL (206) 381-6071

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Telephone: (206) 587-0430

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

May 1, 2002
Date


D. F. Lindholm

Appendix to Second Preliminary Amendment filed April 30, 2002

In the Specification:

The title has been replaced as follows:

**-- NUCLEIC ACID MOLECULES ENCODING
SIGIRR [DNA AND] POLYPEPTIDES --**

In the Claims:

--34. (new) An isolated nucleic acid molecule that hybridizes to the nucleic acid depicted in SEQ ID NO:1 in 50% formamide and 6XSSC, at 42°C and after washing conditions of 60°C, 0.5XSSC, 0.1% SDS, and encodes an amino acid sequence that is at least 80% identical to amino acids 1-118 of SEQ ID NO:2.

35. (new) The isolated nucleic acid molecule of claim 34, wherein said amino acid sequence is at least 90% identical to amino acids 1-118 of SEQ ID NO:2.

36. (new) The isolated nucleic acid molecule of claim 34, encoding an amino acid sequence comprising amino acids 1-118 of SEQ ID NO:2.

37. (new) An isolated nucleic acid molecule that hybridizes to the nucleic acid depicted in SEQ ID NO:1 in 50% formamide and 6XSSC, at 42°C and after washing conditions of 60°C, 0.5XSSC, 0.1% SDS, wherein said molecule is at least 80% identical to the nucleic acid sequence of SEQ ID NO:1.

38. (new) The isolated nucleic acid molecule of claim 37, wherein said molecule is at least 90% identical to the nucleic acid sequence of SEQ ID NO:1.

39. (new) The isolated nucleic acid molecule of claim 38 comprising the nucleic acid sequence of SEQ ID NO:1.

40. (new) The isolated nucleic acid molecule of claim 37 encoding an amino acid sequence comprising the sequence of SEQ ID NO:2.

41. (new) A recombinant vector that directs the expression of the nucleic acid molecule of claim 34.

42. (new) A recombinant vector that directs the expression of the nucleic acid molecule of claim 35.

43. (new) A recombinant vector that directs the expression of the nucleic acid molecule of claim 36.

44. (new) A recombinant vector that directs the expression of the nucleic acid molecule of claim 37.

45. (new) A recombinant vector that directs the expression of the nucleic acid molecule of claim 38.

46. (new) A recombinant vector that directs the expression of the nucleic acid molecule of claim 39.

47. (new) A recombinant vector that directs the expression of the nucleic acid molecule of claim 40.

48. (new) A host cell or its progeny transfected or transduced with the vector of claim 41.

49. (new) A host cell or its progeny transfected or transduced with the vector of claim 42.

50. (new) A host cell or its progeny transfected or transduced with the vector of claim 43.

51. (new) A host cell or its progeny transfected or transduced with the vector of claim 44.

52. (new) A host cell or its progeny transfected or transduced with the vector of claim 45.

53. (new) A host cell or its progeny transfected or transduced with the vector of claim 46.

54. (new) A host cell or its progeny transfected or transduced with the vector of claim 47.

55. (new) The host cell of claim 48, 49, 50, 51, 52, 53, or 54, wherein the host cell is a bacterial cell.

56. (new) The host cell of claim 48, 49, 50, 51, 52, 53, or 54, wherein the host cell is a yeast cell.

57. (new) The host cell of claim 48, 49, 50, 51, 52, 53, or 54, wherein the host cell is a plant cell.

Immunex Corporation
USSN 09/598,443

Attorney Docket No. 2007-US

58. (new) The host cell of claim 48, 49, 50, 51, 52, 53, or 54, wherein the host cell is an animal cell.

59. (new) A method for the production of TIGIRR polypeptide comprising culturing the host cell of claim 48, 49, 50, 51, 52, 53, or 54 under conditions promoting expression.

60. (new) The method of claim 59, further comprising recovering the polypeptide from the culture medium.--